HANSOH PHARMA(HK:03692) Haitong Securities International·2025-10-17 03:51Investment Rating - The report maintains a positive outlook on Hansoh Pharmaceutical, indicating an expectation of outperforming the market in the next 12-18 months [15]. Core Insights - Hansoh Pharmaceutical has entered into a licensing agreement with Roche for HS-20110 (CDH17 ADC), which includes an upfront payment of USD80 million and potential milestone payments of up to USD1.45 billion, along with royalties on product sales [5][6]. - The company anticipates significant growth in milestone revenues and out-licensing opportunities, with management raising the full-year revenue guidance to mid-to-high double-digit growth [6][7]. - Revenue from innovative drugs is projected to exceed CNY10 billion in 2025, with innovative drug revenue likely surpassing 80% of total revenue [6][7]. - The core product Aumolertinib is expected to achieve sales exceeding CNY6 billion in 2025, with peak sales potential reaching CNY8 billion [7]. Summary by Sections Licensing Agreement - Hansoh has licensed HS-20110 (CDH17 ADC) to Roche, receiving an upfront payment of USD80 million and up to USD1.45 billion in milestone payments tied to development and commercialization [5][6]. Revenue Growth - The company’s milestone revenues for the first half of 2025 have significantly exceeded expectations, prompting an upward revision of the revenue guidance [6]. - Combined milestone and upfront payments are projected to exceed CNY2.2 billion [6]. Product Pipeline - Aumolertinib has received approval for four indications, with anticipated sales growth and further approvals expected to solidify its market position [7]. - The early-stage pipeline includes innovative molecules like EGFR/cMET ADC and CDH6 ADC, which present out-licensing opportunities [6].